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Abstract 
Hepatocellular carcinoma is a malignant disease with improved hepatic regeneration and survival, 
and is activated by human telomere transferase (hTERT). hTERT is expressed during early fetal 
development and switched off in most adult tissues, but it becomes reactivated in HCC. The exact 
mechanism regulating these expression changes remains unknown during HCC progress. We 
evaluated the relationship between hTERT expression and human kruppel-related 3 (HKR3) and cell 
cycle-related factors in HCC cell lines. Following transfection for hTERT knockdown and HKR3 
overexpression, proteomic and transcriptomic analyses related to hTERT were performed using 
liquid chromatography/mass spectrometry (LC/MS) and RNA sequencing (RNAseq) in HCC cell 
lines. The expression levels of hTERT, HKR3, and cell cycle-related factors were measured using 
western blotting, and tumor growth were evaluated via cell proliferation and cell cycle assays. 
Transcriptomic and proteomic analyses showed that HKR3, hTERT and cyclin-dependent kinase 
inhibitor 2A (CDKN2A) were correlated. Up-regulation of HKR3 expression decreased hTERT and 
cyclin activation and suppressed the G1/S phase of the cell cycle through CDKN2A activation. Our 
results suggest that HKR3 induced regulation of cell cycle through hTERT inhibition and CDKN2A 
activation. Our results will facilitate further exploration of the pathways regulating human 
telomerase activity in HCC cell lines. 
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Background 
Hepatocellular carcinoma (HCC) is the sixth 
most common cancer worldwide and forms 
malignant tumors with poor prognosis [1,2]. Its 
progression is marked by the sequential accumulation 
of genetic and epigenetic abnormalities that give rise 
to a set of common characteristics including the ability 
to promote cell proliferation and escape apoptosis [2]. 
Loss of sensitivity to apoptosis and up-regulation of 
the cell cycle contribute to tumor progression and 
metastasis and determine how cancer cells respond to 
treatment [3]. Therefore, deciphering how the cell 
cycle and apoptosis are regulated in HCC cells is 
important to understanding how these tumors 
develop and improving their clinical management [4]. 
The regulation of cell proliferation is a complex 
process involving numerous transcription factors and 
regulatory proteins [5]. HCC proliferation is 
controlled by the dynamic regulation of the 
expression of oncogenes and tumor suppressor genes 
in response to various signals [5,6]. Telomerase plays 
a key role in conferring immortality to cancer cells 








synthesizes telomeric repeats at the ends of 
chromosomes and replaces end sequences that are 
progressively lost during each cell cycle, allowing 
cells to escape mortality and continue to proliferate 
[7,8]. Reverse transcriptase telomerase is composed of 
two core components, a ubiquitously expressed RNA 
component and a catalytic subunit, human telomerase 
reverse transcriptase (hTERT) [8,9], whose expression 
is limited to the formation of a catalytically active 
enzyme and the regulation of telomerase activity 
[10,11]. Increased telomerase activity (TA) is observed 
in 90% of human cancer cells [8,9]; however, 
telomerase activity is low or undetectable in most 
normal human somatic cells [9]. Therefore, inhibition 
of hTERT could be an effective anti-tumor strategy in 
HCC treatment. 
Previous studies on several cancer cell lines have 
indicated that inhibiting telomerase, particularly 
hTERT, using antisense RNAi is highly promising as a 
cancer therapy [12]. Plasmid-encoding hTERT-specific 
shRNAs have been transfected into human 
hepatocellular carcinoma cell lines and have been 
found to stably suppress hTERT expression [12,13], 
leading to the inhibition of cell proliferation and 
attenuation of tumorigenic potency [14]. The 
transfection of encoding hTERT-specific siRNAs into 
human breast cancer cell lines has been shown to 
inhibit cell proliferation and induce cell apoptosis 
[15]. Recently, several studies have also proved that 
the knockdown of hTERT effectively inhibits the 
expression of telomerase activity, cell proliferation, 
and apoptosis in variable tumor cells in vitro 
[12,14-16].  
As the role of hTERT in HCC increases, studies 
on factors that correlate with hTERT are actively 
proceeding. Although it was confirmed that 
steroidogenic acute regulatory protein (StAR) was the 
factor that increased the expression of hTERT, the 
negative activity of hTERT is regulated by HKR3 
(ZBTB48), but it is not clear [17]. HKR3 is a relatively 
uncharacterized POK family protein with a 
POZ-domain and 11 zinc finger domains [18,19]. 
HKR3 is ubiquitously expressed in human tissues 
[20]. The HKR3 gene is mapped to human 
chromosome 1p36, which is commonly rearranged 
(leiomyoma and leukemias) or deleted 
(neuroblastoma, melanoma, Merkel cell carcinomas, 
pheochromocytoma, and breast and colon 
carcinomas) in various cancers [19,21]. A correlation 
between deletions or rearrangements of HKR3 and 
human cancer suggests a role for HKR3 as a potential 
tumor suppressor [19,21]. 
Since expression of hTERT is highly maintained 
in HCC, the expression of co-related factors involved 
in survival or growth by hTERT remains high [22]. As 
well, although the cell survival in phenomena such as 
regulation of apoptosis by hTERT is known [11], those 
involving hTERT and HKR3 remain poorly 
understood in HCC. Therefore, we examined the 
effects of hTERT knockdown and HKR3 
overexpression on cell proliferation, cell apoptosis, 
and the cell cycle, and evaluated the relationships 
between hTERT expression and both HKR3 and 
CDKN2A in HCC cell lines. 
Materials and Methods 
Patient samples 
Tumor tissues and matched adjacent non-tumor 
liver tissues were obtained with informed consent 
from HCC patients who underwent curative resection 
between 2012 and 2017 at Severence Hospital (Yonsei 
University College of Medicine, Seoul, Republic of 
Korea). A total of 42 pairs of primary HCC tumor 
tissues and matched normal tissues were used for real 
time quantitative PCR, immunohistochemistry. The 
study was conducted in accordance with the ethical 
guidelines of the Declaration of Helsinki and 
approved by the Ethics Committee of Severence 
Hospital. 
Cell culture 
Huh-7(KCLB60104, Korean Cell line Bank), 
Hep3B (KCLB88064, Korean Cell line Bank), and 
HepG2(KCLB88065, Korean Cell line Bank) cells were 
cultured at 37°C with 5% CO2 in Dulbecco’s Modified 
Eagle Medium (DMEM; Gibco, Grand Island, NY) 
supplemented with 10% fetal bovine serum (FBS; 
Gibco, CA, USA), 4.5 g/L glucose, L-glutamine, and 
1% penicillin/streptomycin. 
small interfering RNA (siRNA), Plasmid 
construction and transfection 
siRNA was synthesized using the following 
sequences: siTERT #1: (Forward) 5’-GUC UUC CUA 
CGC UUC AUG Utt-3’, (Reverse) 5’-ACA UGA AGC 
GUA GGA AGA Ctt-3’ (Santa cruz, CA, USA). This 
vector is pcDNA3.1, which is generally used to induce 
the expression of a specific sequence. We constructed 
a plasmid for overexpressing full length HKR3 
(NM_001278647.1). Cells were transfected with 
respective siRNAs using Fugene HD transfection 
agent (Promega, Madison, WI, USA) according to the 
manufacturer’s instructions. After transfection, the 
cells were incubated at normal conditions (21% O2) for 
6 h, then replaced with fresh culture medium.  
Cell Growth Assay 
HCC cell growth rates were measured using the 
WST-1 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophe-
nyl)-5-(2,4-disulfophenyl)-2H-tetrazolium (WST-1, 




Sigma-Aldrich, CA, USA) method. First, the cells were 
seeded in a 96-well plate at 5 x 103 cells/well, 
incubated at 37°C for 24 hours, transferred to 
serum-free medium, and transfected with siRNA as 
described above. Then, after cultivation under 21% O2 
for 24 hours, the cells were transferred to a culture 
medium containing 10% FBS. Finally, WST-1 was 
added to the wells, and the plates were incubated at 
37°C for 3~4 hours for efficient cell dyeing, and 
analyzed for its absorbance at 460 nm using a 
spectrophotometer (Molecular Devices, USA). 
Cell cycle and death assay – FACs  
Cells were stained with FITC-labeled annexin V 
and propidium iodide, and tumor cell death was 
assessed by terminal deoxynucleotidyl transferase 
dUTP nick end labeling (TUNEL; Millipore, Billerica, 
MA, USA) assay and flow cytometry (BD- Flow JO). 
Cell cycle samples also were stained propidium 
iodide (PI) staining) after EtOH fixation at 4oC, O/N. 
mRNA isolation and real-time RT-PCR  
For real-time reverse transcription PCR 
(RT-PCR) studies, cells were seeded in 6-well plates 
until complete adhesion (85% to 90% confluence) and 
then incubated overnight in serum conditions. mRNA 
levels of human TERT, HKR3 and cell cycle factors 
were determined using SYBR Green–based 
semi-quantitative PCR. RNA was extracted using a 
QIAGEN Rneasy mini kit (QIAGEN, Hilden, 
Germany) according to the manufacturer’s 
instructions and reverse-transcribed (RT) using a 
Clontech RT Kit (Clontech, Terra-bella, CA, USA). 
After the RT reaction, qPCR analysis was performed 
using an applied biosystem syber green master mix 
and specific PCR primers (Table S1). Amplification 
efficiencies were calculated for all primers utilizing 
serial dilutions of the pooled cDNA samples. The data 
were calculated, using the comparative (ΔΔCt) 
method, as the ratio of each gene to the expression of 
beta actin, the housekeeping gene. Data are shown as 
mean ± s.e.m. (error bars) of at least three 
independent experiments and represented as 
fold-change vs. controls. Melting curves were 
generated to ensure a single gene-specific peak, and 
no-template controls were included for each run and 
each set of primers to control for unspecific 
amplifications.  
Immuno-blot analysis.  
The effects of inhibition of hTERT expression on 
the expression of proteins related to cell cycle and 
apoptosis were assessed using immuno-blot. Total 
proteins were collected from siTERT and HKR3 
transfected HCC cells after they were incubated under 
culture conditions for 24 hours and lysed. The 
proteins were separated according to their molecular 
weight via sodium dodecyl sulfate–polyacrylamide 
gel electrophoresis, transferred to a polyvinylidene 
fluoride membrane (GE Healthcare, Amersham, 
Buckinghamshire, UK), and probed with mouse 
monoclonal antibodies specific for the proteins of 
interest. The blots were developed using the ECL 
technique (PerkinElmer, Boston, MA, USA) according 
to the manufacturer’s instructions, and the level of 
expression of each protein was quantified and 
compared (hTERT, HKR3, CDKN2A and CDKN2B: 
Invitrogen, Cambridge, MA, USA; Cyclin B1, Cyclin 
D1 and Cyclin E1 : Cell signaling, Danvers, MA, USA; 
CDK2 and CDK4: Santa cruz, CA, USA). For the 
detection of cellular proteins as hTERT, an 
enzyme-linked immunosorbent assay (ELISA; R&D 
Systems, CA, USA) was performed according to the 
manufacturer’s instructions. IHC also used same 
antibodies. The obtained sections were subjected to 
dewaxing in xylene and dehydration in several 
graded ethanols, then heated to 100 °C in 0.1 M citrate 
buffer (pH 6.0) for 30 min to retrieve the antigens. 3% 
H2O2 was used to block the activity of endogenous 
peroxidase for 10 min, then incubated with the 
indicated primary antibody (anti-TERT and 
anti-HKR3) overnight at 4 °C. After washing with 
PBST (with 0.5% Tween-20), xenograft or patients 
tissues were incubated with secondary antibodies, 
comprising horseradish peroxidase-conjugated 
anti-rabbit or anti-mouse IgG (Envision kit, Dako, 
Denmark). Finally, the hematoxylin-stained sections 
were observed under an Axio Observer A1 
microscope (Carl Zeiss, Jena, Germany). 
Transcriptomic and proteomic analyzes were 
confirmed by RNAseq and LC / MS. The above 
analysis was performed as described in Supporting 
Materials and Methods. 
Statistical analysis  
Results were expressed as means ± standard 
error of the mean (SEM) or frequency (%). An 
independent t-test was performed to compare the 
difference of the means between control and 
experimental groups. All statistical analysis was done 
using SPSS version 12.0 (SPSS, Inc., Chicago, IL). A p 
value of less than 0.05 was considered statistically 
significant. 
Results 
1. hTERT is highly expressed in HCC. 
In order to identify factors controlling hTERT, 
we first examined the expression pattern of hTERT in 
HCC tissues. To confirm increased hTERT expression 
in HCC, 42 patients with hepatocellular carcinoma 
underwent rt-qPCR. HCC tissues showed 




approximately 15 times more hTERT expression than 
normal tissues (Fig. 1A), and immunohistochemistry 
(IHC) results also indicated increased hTERT 
expression in HCC tissues (Fig. 1B). Based on these 
results, most of the patients with HCC showed high 
expression of hTERT. 
2. Identification of hTERT related factors by 
transcriptomic analysis 
In order to investigate the factors regulating the 
expression and activity of hTERT, and it was inhibited 
using small interfering hTERT (siTERT). (Figure 1C, 
D). After suppression of hTERT expression, changes 
in mRNA expression were analyzed via RNAseq. 
Although changes in genes related to apoptosis were 
the most frequent, we also observed changes in cell 
cycles and senescence-related genes (Figure 1E, Figure 
S1A). So, we also detected genes controlling hTERT 
expression and confirmed that HKR3 and hTERT 
were correlated. Consequently, rt-qPCR results 
showed that hTERT expression occurred more 
frequently in non-HCC than in HCC (Figure 2A). 
However, IHC results revealed almost no HKR3 
expression within cancer tissues of HCC patients; 
instead, HKR3 was found mainly around the bad 
prognosis of liver tissue, not HCC (Figure 2B). When 
hTERT and HKR3 expression were compared in cell 
strains, hTERT was more evident in cell strains of 
HCC, whereas HKR3 appeared more frequently 
normal cell strains (Figure 2C, D). After confirmation 
of HKR3 overexpression and hTERT knockdown 
(Figure 2E), analysis of hTERT-derived genes in HKR3 
overexpression based on RNAseq analysis yielded 
similar pattern of hTERT knockdown. The cell cycle 
and cell death-related changes are 26-29% of the total 
changes, and other changes such as cell 
communication, metabolic process, cellular 
components can be identified (Figure S1B). In other 
words, we observed gene expression related to 
apoptosis and changes in gene expression related to 
the cell cycle (Figure 2F), indicating that the genes 
involved with HKR3 and hTERT are closely 
correlated.  
3. Verification of transcriptomic results for 
hTERT and HKR3 by proteomic analysis 
To verify consistency between the results of 
dielectric and proteome analyses, we conducted 
LC/MS analyses. A total of 3,500 proteins were 
detected in HCC cell lines. Of these, 1,408 (40.2%) 
proteins were commonly expressed in each groups. 
By contrast, 625 and 567 were expressed uniquely in 
control groups (NT and NC groups) and experimental 
groups (HKR3 and siTERT groups), respectively 
(Figure S1C). In addition, the expression levels of 585 
of the 2,127 proteins in HKR3 groups and 851 of the 
 
 
Figure 1. hTERT expression and its correlation with HCC. hTERT was overexpressed in HCC. (A) hTERT expression in tissues of 42 HCC patients was confirmed by 
real-time quantitative polymerase chain reaction (qPCR). Expression was higher in the HCC group than in the non-HCC group. (B) Immunohistochemistry results also showed 
that hTERT expression was higher in the HCC group than in the non-HCC group. (C, D) siTERT activity was confirmed by qPCR and Western blotting. hTERT expression was 
inhibited by ≥80% (NC vs *p < 0.05, **p < 0.001). All experiments were repeated three times. (E) Heatmap, volcano plot, and scatter plot of the 40 most differentially expressed 
genes between control and hTERT knockdown Hep3B cells determined by RNA sequencing (RNAseq) analyses (≥2 fold change, p ≤ 0.05).  




2,486 proteins in siTERT groups were altered by at 
least 2.0-fold compared to NC groups, or uniquely 
identified. Proteins with an expression level of mol % 
> 0.001 were selected for DEG analysis and used for 
post analysis. Similar patterns of protein expression 
among the siTERT group and the HKR3 
over-expression group were obtained (Figure 3A). 
Proteomic analysis shows that binding and catalytic 
activity are similar patterns. On the other hand, 
different patterns can be identified in structure, 
transport and signal transducer. Based on these 
results, we observed a change in protein expression 
that was analogous to that observed in our RNAseq 
dielectric analyses (Figure 3B). Apoptosis or survival 
related gene changes were most consistent in the same 
results of RNAseq and proteomic analysis. 
Subsequently, analysis of changes in cell structure, 
cell cycle and cell proliferation was highly consistent. 
Based on results of the cell cycle, cell proliferation and 
cell death, Ingenuity pathway analyses (IPA) of the 
protein network in the hTERT suppression/HKR3 
overexpression group showed that hTERT is 
regulated by STAT3, is associated with cell 
differentiation factors, and predicts to modulate 
CDKN2A. HKR3 is associated with cell respiration, 
apoptosis factors, and also regulated CDKN2A 
(Figure 3C). Interestingly, both HKR3 and hTERT 





Figure 2. HKR3 expression and hTERT regulation. (A) HKR3 expression in tissues of 42 HCC patients was confirmed by real-time qPCR. hTERT expression was higher 
in the non-HCC group than in the HCC group. (B) Immunohistochemistry results also showed that HKR3 expression was higher in the non-HCC than in the HCC group. (C, 
D) hTERT and HKR3 expression was confirmed in various cell lines. The results of qPCR and Western blotting showed high hTERT expression in liver cancer cell lines HepG2, 
Hep3B, and Huh7, and high HKR3 expression in normal cell lines H9C2 and HEK293. All experiments were repeated three times. (E) siTERT activity and HKR3 overexpression 
were confirmed by rt-qPCR. HKR3 expression was increased by ≥ 4 times (NC vs or Empty vs *p < 0.05, **p < 0.001). All experiments were repeated three times. (F) Heatmap, 
volcano plot, and scatter plot of the 944 most differentially expressed genes between control and hTERT knockdown Hep3B cells determined by RNAseq (≥2 fold change, p ≤ 
0.05).  





Figure 3. Proteomic analyses of hTERT and HKR3. We performed ingenuity pathway analyses (IPA) of 268 differentially expressed proteins identified from a comparison 
between siTERT and HKR3 overexpression groups using an edge rank algorithm. (A) Protein functions of siTERT and HKR3 were showed by Venn diagram (B) A network for 
biological process of connected pathways identified between siTERT and HKR3 by liquid chromatography/mass spectrometery (LC/MS). Red, upregulated; blue, downregulated. 
(C) Other interacting molecules (Red: up-regulation, Green: down-regulation, Orange: Predicted as up-regulation, Blue: Predicted as down-regulation) 
 
4. HKR3 inhibits hTERT expression and 
activation of CDKN2A 
Factors related to the cell cycle were verified in 
the hTERT knockdown and HKR3 expression groups 
based on results of the transcriptomic and proteomic 
analyses. hTERT expression decreased with increases 
in HKR3 expression in the siTERT and HKR3 
overexpression groups (Figure 4A). We confirmed 
mRNA expression in factors related to the cell cycle 




through qPCR and observed that CDKN2A 
expression was increased (Figure 4B), whereas the 
expressions of cyclin A1, B1, and D1, which are 
controlled by CDKN2A, were reduced (Figure 4C). 
Both CDKN2A groups showed an upward trend in 
protein expression, whereas cyclin A, B, and D 
experienced decreased expression (Figure 4D). In 
addition, CDKN1A, which showed a slight increase in 
rt- qPCR results (Figure 4B), also slightly increased 
(Figure 4E). We also confirmed that p53, p21, and 
MDM2, which is the major tumor suppressor protein 
involved in the cell cycle, was correlated with hTERT 
or HKR3 expression. As a result, p53 was significant 
with siTERT or HKR3 group, while p21 and MDM2 
were not significant. On the other hand, Aurora 
kinase A and B (AURKA and AURKB), the cell cycle 
accelerate protein, were significantly decreased in 
hTERT knockdown or HKR3 overexpression group 
(Figure 4F). Based on these results, hTERT is 
suppressed by HKR3, and CDKN2A is activated by 
the suppressed hTERT.  
5. CDKN2A inhibits cell cycle arrest in HCC by 
inhibiting hTERT via HKR3 
As the results of the protein and mRNA-level 
analyses, we performed cell proliferation and cell 
cycle assays and found that hTERT and HKR3 
controlled the cell cycle. Cell proliferation was 
inhibited in both siTERT and HKR3 overexpression 
groups in Hep3B and Huh7, time-dependently 
(Figure 5A). Both groups showed inhibitory effects 
after 24 hours. In HCC cell lines, about 50% inhibition 
effect was confirmed in the siTERT treated group and 
the inhibitory effect of about 70% was confirmed in 
HKR over-expression group. Furthermore, both 
groups showed cell cycle arrest in the G1/S phase 
(Figure 5B). Based on these results, we conclude that 
the cell cycle was inhibited by CDKN2A when hTERT 





Figure 4. Changes in cell cycle factors identified by hTERT knockdown and HKR3 overexpression. We confirmed the findings of our transcriptomic and proteomic 
analyses by performing qPCR and Western blotting. (A) hTERT and HKR3 expression in the siTERT and HKR3 overexpression groups was confirmed by Western blotting; 
hTERT expression decreased in both groups. (B) The expression of cell cycle factors in the siTERT and HKR3 overexpression groups was confirmed by qPCR. CDKN1A and 
CDKN2A expression was higher in the hTERT suppression and HKR3 overexpression groups than in the control group (NC vs or Empty vs *p < 0.05, **p < 0.001). (C) In siTERT 
and HKR3 overexpression, expression of cyclins and cyclin dependent kianses (CDKs) was detected and confirmed by rt-qPCR (NC vs or Empty vs *p < 0.05, **p < 0.001). (D) 
Western blotting results indicated that CDKN2A expression was higher in the hTERT knockdown and HKR3 overexpression groups than in the control group. However, cyclin 
A1 and B1 were higher in the control group than in the hTERT knockdown and HKR3 overexpression groups. (E) CDKN1 slightly increased in siTERT and HKR3 compared to 
control. (F) In siTERT and HKR3 overexpression, expression of AURK, p53, p21 and MDM2 was detected and confirmed by rt-qPCR (NC vs or Empty vs *p < 0.05, **p < 0.001). 
All experiments were repeated three times. 





Figure 5. Regulation of cell cycle and cell proliferation by hTERT knockdown and HKR3 overexpression. (A) The inhibition of cell proliferation was greater in the 
siTERT and HKR3 overexpression groups than in the control group, in a time-dependent manner. The inhibitory effects of HKR3 overexpression were greater than those of the 
hTERT knockdown group (NC vs or Empty vs *p < 0.05, **p < 0.001). (B) FACs-PI staining was performed to confirm cell cycle arrest by siTERT and HKR3. Cell cycle arrest in 
the G1/S phase was observed to a greater extent in hTERT knockdown and HKR3 overexpression groups than in the control group. All experiments were repeated three times. 
 
Discussion 
HCC is a malignant disease belonging to a high 
risk group which is difficult to treat due to various 
mutations and drug metabolic functions of the liver. 
In particular, hepatocellular carcinoma is difficult to 
treat due to many obstacles characterized by 
heterozygous mutations. Especially hTERT promoter 
mutation, which is one of the mutations, has a great 
influence on the progress of HCC [23,24]. Besides, 
Regenerative tissues such as the liver are similarly 
regulated in tumors using hTERT, STAT, MAPK 
signal, et al. [25]. On the other hand, HKR3 inhibited 
the expression of hTERT and decreased telomere 
activity in early cancer [17]. Inhibition of hTERT has 
been reported to inhibit cyclin activity [26]. Therefore, 
the correlation between hTERT, HKR3 and cell cycle 
factors can be confirmed. Peculiarly, hTERT-mediated 
cell cycle regulation in HCC has a great effect on 
tumor viability. Therefore, since various hTERT 
signals are not well known, studies on HCC and 
hTERT are being performed continuously. Based on 
this fact, we detected the overexpression of hTERT in 
HCC cells. The results revealed an arrest of cell cycle 
and an increase of apoptosis induced by the 
knockdown of hTERT and HKR3 overexpression in 
HCC cells, indicating that the down-regulation of 
hTERT had the potential anticancer effects in HCC. 
Therefore, studies on the regulation of hTERT have 
been conducted in the development of anticancer 
drugs and therapies in HCC. 
Several studies have explored the correlation 
between hTERT and tumors such as leukemia, 
cervical cancer, breast cancer, and HCC 




[8,14,15,22,27]. Aging of natural cells through 
reduction of telomere causes apoptosis, or apoptosis 
also occurs through hTERT inhibition. Thus, 
over-expression of hTERT leads to the synthesis of 
telomeres to prevent apoptosis in most solid tumors 
[11]. However, whether hTERT leads the cell cycle by 
inhibiting factors other than telomeres, including 
CDKN2A, has remained unknown. The current study 
demonstrated that hTERT expression is not limited to 
anti-apoptosis and tumor survival but also affects the 
tumor cell cycle [11,14]. We also confirmed that 
inhibition of hTERT induces apoptosis (Figure S2). So, 
we investigated the mechanism controlling the cell 
cycle using the link connecting HKR3, which 
regulates hTERT, to CDKN2A, which is regulated by 




Figure 6. Schematic of hypothetical HKR3 signaling cascade. 
Mechanistically, short telomeres activate p53 that induces cell cycle arrest. Blunting 
telomere shortening via overexpression of hTERT. And, HKR3 inhibits the 
expression of hTERT and binds telomere to inhibit the activity of hTERT. 
 
Changes in gene expression following the 
suppression of hTERT expression were observed in 
RNAseq analyses. Among these changes, the major 
one is apoptosis, with genes related to cell cycle 
progression and cytoplasm organization showing the 
most changes. Differentially expressed gene analyses 
were conducted to explore telomere-related genes 
including StAR, hTERT-related gene that up-regulates 
HDAC and hTERT, and HKR3, which inhibits hTERT 
expression. Changes in gene expression are induced 
by suppressing hTERT expression and overexpressing 
HKR3; we observed a similar pattern of gene changes 
in this study. Most changes occurred in genes related 
to apoptosis, followed by those involved in the cell 
cycle. 
For background studies on the variable disease, 
many researchers carry out RNAseq or 
next-generation sequencing (NGS), a transcriptomic 
analysis [28-30]. Other researchers perform proteomic 
analysis by considering protein modification more 
important than gene expression [31,32]. Most of the 
expression of the genome is linked to the activity of 
the protein, but it may be removed before the protein 
is activated, or it may function differently from its 
original role [33]. On the other hand, very few 
genomic expressions have potent protein activity [34]. 
It may be over-expressed in certain conditions and 
may be involved in various biological processes due 
to intracellular accumulation such as HIF by hypoxia 
[35]. The results were similar to those of 
transcriptomic analyses, with similar patterns 
observed in protein changes associated with 
apoptosis, the cell cycle, and cell structure.  
Similar changes in protein expression were 
observed in the hTERT inhibition and HKR3 
overexpression groups. However, the regulation of 
HKR3 expression involved more gene and protein 
changes in more areas compared to those for hTERT, 
which is involved in telomere synthesis in the 
nucleus. This differential expression can be explained 
by the fact that HKR3 is a telomeric zinc 
finger-associated protein that controls telomere 
elongation and acts as a transcription activator [19], 
regulating the expression of various genes. Previous 
studies have reported that HKR3 inhibits ARF 
expression and cell proliferation in the ARF region 
[36,37], indicating that among various 
tumor-suppressing functions, HKR3 also acts as a 
regulator of the cell cycle, which is controlled by ARF 
and cell proliferation [19,36,38,39]. 
However, less research has been conducted on 
HKR3 than on hTERT. Thus, this result confirms the 
correlation between HKR3 and hTERT, thereby 
establishing a linkage that regulates the cell cycle. 
Namely, the cell cycle and apoptosis of HCC were 
regulated by hTERT. In addition, it was confirmed 
that hTERT expression was inhibited by HKR3. 
Moreover, p53 is activated by the short telomere, 
which leads to cell cycle arrest [40]. Therefore, HKR3 
regulates cell cycle and apoptosis of HCC through 
regulation of TERT (Fig. 6). Based on these results, 
further studies of the mechanism by which HKR3 
expression is suppressed in HCC and the roles of 
HKR3 in transcription activation and HCC 
progression are required. These studies will be used 
as background data for clinical application of 
recombinant proteins such as HKR3 in HCC. We also 
anticipate that our results will be used to promote 
treatment that can prevent the HCC progress through 
the inhibition of hTERT using HKR3. 
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